A meeting of the Commercial Product Delivery Committee of the Citrus Research and Development Foundation, Inc. was held on Thursday, September 18, 2014 at 9:30 a.m. at the Ben Hill Griffin Hall, Lake Alfred, Florida. The meeting was properly noticed and recorded. The meeting was called to order by Chairman Ben McLean at 9:30 a.m. Roll was called and a quorum was present. Committee members participating were: Dr. Timothy L. Anglea (telephone); Mr. Larry Black; Mr. Joe L. Davis, Jr.; Dr. Mary L. Duryea; Mr. David Howard; Mr. Ricke Kress (telephone); Mr. Peter McClure (telephone); Mr. Ben McLean; Mr. Jerry Newlin; Mr. Andy Rackley; Ms. Shannon Shepp; and Mr. Tom Stopyra. Mr. Hugh Thompson did not participate. Also participating in the meeting were Dr. Richard Beeson; Dr. Harold Browning; Dr. James Dukowitz; Dr. James Keesling; Mr. Phillip Rucks; Ms. Stephanie Slinski; Dr. Jim Syvertsen and Dr. Tom Turpen. Also in attendance were: Ms. Brandi Goller; Dr. David G. Hall; Ms. JoAnn Lee; Mr. Brandon Page; Mr. Ross Ptacek; Ms. Gail Weinkauf and Ms. Audrey Nowicki.

Ms. Shepp moved to accept the Minutes of the July 1, 2014 Committee meeting. The motion was seconded by Mr. Newlin and passed unanimously.

Mr. Rackley made a motion to accept the Minutes of the September 11, 2014 meeting held in Atlanta, seconded by Mr. Stopyra. Mr. Stopyra suggested a summary from the two previous days of the IR-4 Conference Mini-Summit be appended to the minutes. It was explained that the September 11th meeting was informational for the CPDC and was noticed as required by the Sunshine Law since multiple CPD Committee members attended the discussion. The presentations from the IR4 Mini-Summit will be available on the web site. The motion to accept the September 11th Minutes passed unanimously.

Dr. Turpen introduced Dr. Stephanie Slinski, the Florida Antimicrobial Project Manager and explained her role in management of Antimicrobial projects within CPDC.

Dr. Turpen reported on the study to identify antibiotics that have been tested and approved on other crops or animals and failed; the full report on this effort will be submitted next month. One compound has been identified that could be re-positioned for citrus and is being evaluated for control of greening. Mr. Black questioned the status of testing Bayer’s compounds; they have been provided and are in the second phase of assay evaluation.

A telephonic conference was held August 28th with many members of the committee participating along with representatives of U.S. EPA, FDA, CDC, FDACS and FFVA to continue discussions of regulatory issues relating to antimicrobial candidates being pursued for HLB therapy, as well as provide a background for discussion at the IR-4 mini-summit.
The September 11th IR-4 mini-summit focused on antimicrobial tools being investigated for specialty crops. Dr. Dukowitz reported that it provided an opportunity for different food groups to discuss their experiences related to the use of antibiotics in treating disease and challenges they face in the regulation process. IR-4 could work alongside the Foundation with a united voice when contacting regulatory agencies in the process to obtain special use labels and product registrations. IR-4 has a set process for replicated trials in different regions and specific to crops of interest. In the meeting following the summit, representatives from the regulatory agencies stressed the importance of timely studies on efficacy and residues, and the need to compile and submit the residue package and application for Section 18 special exemptions. The regulatory agencies stressed the importance of continued communication, keeping them apprised of the progress toward future applications.

Dr. Anglea suggested comparing candidate antimicrobial materials against different factors influencing their availability, i.e. what is the fastest way to get antibacterials into the grove, rating the regulatory path and social acceptance among the other factors when prioritizing candidates for further action.

The AgroSource projects are progressing, with a meeting and report due in October. There was a discussion of NuFarm’s activities related to antimicrobials and that the Foundation should approach representatives to get specifics of their projects, whether the required residue analyses are being performed, and if Foundation support would bring faster results.

Dr. Dawson and Dr. Keesling of UF gave presentations on their progress with the layout and modeling for the psyllid shield concept. Their presentations can be found on the web page with the meeting materials. Dr. Turpen requested guidance from the Committee on whether or not to pursue grove and border simulations using current crop conditions provided through CHMA data. He also indicated the timeliness of initiating discussions with EPA on regulatory paths to be followed.

Dr. Browning reported on the tolerant rootstocks program, reminding of the ongoing project to propagate USDA and UF candidate tolerant rootstocks for spring field trial planting. He introduced a proposal for a process to overcome the current limitations on nursery stock availability as well as controlling canker in the nursery stock, topics which were included in the IRCC Gaps Analysis report. Dr. Browning asked Mr. Rucks and Dr. Beeson to discuss the proposal for nursery propagation support. Mr. Rucks reinforced the need for this project and Dr. Beeson summarized his proposal to accelerate the production of quality budded trees for outplanting in groves for all producers to take advantage of future research results with rootstocks. The project will develop guidelines for seed propagation that prevents contamination of seed by citrus canker, and will investigate best practices for root cuttings and micro-propagation of rootstocks. Information on the best methods will be shared with all nurserymen at a yearly workshop. Mr. Newlin moved to recommend Dr. Beeson’s project “propagation of rootstock tree production in greenhouses by seed, stem cuttings and tissue culture to accelerate budded tree production for outplanting” including the addition to the greenhouse, for three years in the total amount of $333,774, seconded by Mr. Stopyra. After discussion of whether or not there is budget available and verification that this is not a duplication of other efforts, the motion passed unanimously.
Dr. Browning provided an update on the MAC funding, noting that the contract for the soil applied antimicrobials field trials which are under way has been executed and the first installment billed. The second contract for the HLB AgroSource project, the large scale laboratory, greenhouse and field trials of HLB bactericidal therapies, is in progress and should be executed within the week.

The USDA, APHIS MAC deadline for submitting new project ideas for funding has passed. Applicants will be notified in the coming weeks of the ideas that will progress to contracting.

Dr. Syvertsen and Mr. Brandon Page are developing evaluation protocols for the thermal therapy scale-up trials. This will allow applications of thermal treatment to be compared against common criteria.

Dr. Dukowitz stated the Quarterly Report included with the meeting materials is as of June 30th and the September 30th report will be provided in October.

With no further business, the meeting was adjourned at 12:30 p.m.

Minutes submitted by Audrey Nowicki